Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Intracerebroventricular BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease

NCT02678689 is registered in ClinicalTrials.gov with BioMarin Pharmaceutical as lead sponsor.

NCT NCT02678689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02678689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Intracerebroventricular BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease
Lead sponsor
BioMarin Pharmaceutical
Phase
Phase 2
Overall status
Completed
Start date
January 22, 2016
Completion date
April 20, 2022
Enrollment
14 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

batten disease, cln2 disease, cln2 disorder, jansky-bielschowsky disease, late-infantile neuronal ceroid lipofuscinosis type 2